Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Key facts
- Where
- Atlanta, Austin, Baltimore, Birmingham, Boston, Buffalo, Chapel Hill, Charlotte, Chicago, Cincinnati, Columbus, Dallas, Denver, Gilbert, Houston, Iowa City, Jacksonville, Little Rock, Los Angeles, Louisville, Madison, Miami, Nashville, New Brunswick, New York, Norfolk, Philadelphia, Portland, Rochester, Salt Lake City, San Antonio, San Francisco, Seattle, St Louis, Tampa, and Westwood, United StatesSee the 41 sites
- Phase
- Phase 2
Where in United States
- Northside HospitalAtlanta, United StatesTaking people
- Winship Cancer Institute of Emory UniversityAtlanta, United StatesTaking people
- AustinAustin, United StatesNo longer taking part
- BaltimoreBaltimore, United StatesNo longer taking part
- University of Alabama at BirminghamBirmingham, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- Roswell Park Cancer InstituteBuffalo, United StatesTaking people
- University of North Carolina Medical CenterChapel Hill, United StatesTaking people
- CharlotteCharlotte, United StatesNo longer taking part
- Northwestern Memorial HospitalChicago, United StatesTaking people
- University of Chicago Medical CenterChicago, United StatesTaking people
- Oncology Hematology CareCincinnati, United StatesTaking people
- The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer CenterColumbus, United StatesTaking people
- UT Southwestern Medical CenterDallas, United StatesTaking people
- Colorado Blood Cancer InstituteDenver, United StatesTaking people
- Banner MD Anderson Cancer CenterGilbert, United StatesTaking people
- University of Texas - MD Anderson Cancer CenterHouston, United StatesTaking people
- University of IowaIowa City, United StatesTaking people
- Mayo Clinic in FloridaJacksonville, United StatesTaking people
- University of Arkansas for Medical SciencesLittle Rock, United StatesTaking people
- UCLA Hematology/Oncology - Westwood (Building 200 Suite 214)Los Angeles, United StatesTaking people
- Norton Women's and Children's HospitalLouisville, United StatesTaking people
- University of Wisconsin Carbone Cancer Center - University HospitalMadison, United StatesTaking people
- Miami Cancer Institute at Baptist Health, Inc.Miami, United StatesTaking people
- Tennessee OncologyNashville, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- Rutgers Cancer Institute of New JerseyNew Brunswick, United StatesTaking people
- Icahn School of Medicine at Mount SinaiNew York, United StatesTaking people
- Memorial Sloan-Kettering Cancer CenterNew York, United StatesTaking people
- Virginia Oncology AssociatesNorfolk, United StatesTaking people
- Sidney Kimmel Cancer Center - Jefferson HealthPhiladelphia, United StatesTaking people
- Oregon Health and Science UniversityPortland, United StatesTaking people
- Mayo Clinic in Rochester, MinnesotaRochester, United StatesTaking people
- LDS HospitalSalt Lake City, United StatesTaking people
- Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant InstituteSan Antonio, United StatesTaking people
- UCSF Helen Diller Medical Center at Parnassus HeightsSan Francisco, United StatesTaking people
- Fred Hutchinson Cancer CenterSeattle, United StatesTaking people
- Washington University School of MedicineSt Louis, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
- The University of Kansas Cancer Center - WestwoodWestwood, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Trial code
- NCT06297226
- Record updated
- 6 October 2026
- Original description
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.Read full original descriptionShow less
A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)
The purpose of this study is to evaluate the effectiveness and safety of Arlocabtagene Autoleucel (BMS-986393) in participants with relapsed or refractory multiple myeloma.
Inclusion: Documented diagnosis of multiple myeloma (MM) as per International Myeloma Working Group (IMWG) criteria; Received at least 4 classes of MM treatment [including immunomodulatory drug (IMiD), proteasome inhibitor (PI), anti CD38 mAb, anti-BCMA therapy, and at least 3 prior lines of therapy (LOT); Documented disease progression during or after their last anti-myeloma regimen as per IMWG 2016 criteria; Participants must have measurable disease during screening; Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Exclusion: Active systemic fungal, bacterial, viral, or other infection despite appropriate anti-infective treatment at the time of leukapheresis. Participants with severe infection, severe sepsis or bacteremia in the last 28 days prior to leukapheresis are excluded; Received any prior therapy directed at G protein-coupled receptor class C, group 5, member D (GPRC5D) or has received other prior treatment for MM without the required washout prior to leukapheresis; Active or history of central nervous system involvement with MM; Other protocol-defined Inclusion/Exclusion criteria apply.